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CA 125, a marker of ovarian cancer, is also increased in
otherwise normal women suffering from, for example, pelvic
inflammatory disease, endometriosis and adenomyosis. The
tissues suspected of producing CA 125 in normal women
include the endometrhim, the ovary and the peritoneum. This
study was based on the hypothesis that uterine myomata
would distend the peritoneum covering the uterus and thereby
increase the peripheral levels of CA 125. To verify this
hypothesis we measured CA 125 by an immunoradiometric
assay in eight normal women every second day throughout
the cycle and in 26 women with uterine fibroids before and
after hysterectomy and at 8 and 12 weeks during gonado-
trophin releasing hormone (GnRH) analogue therapy. In
normal women no difference was observed between CA 125
levels in the follicular phase or in the hiteal phase of the cycle.
Over one-third (10/26) of the patients with uterine fibroids
had increased (>90th centile of the controls) levels of CA 125
before GnRH therapy or hysterectomy. Removal of the uterus
or administration of GnRH significantly decreased peripheral
concentrations of CA 125 to levels below those observed in
normal women. Furthermore, a significant positive correla-
tion was observed between the levels of CA 125 and the
volume of myomata as assessed by ultrasound. We conclude
that in those cases of uterine fibroids where CA 125 is
increased, monitoring this parameter during GnRH therapy
is a good indirect measurement of regression of myomata.
Key words: CA 125/uterine fibroids/GnRH therapy versus
hysterectomy
Introduction
OC 125 is a murine monoclonal antibody recognizing a determi-
nant on an antigen called CA 125. The elevated serum
concentrations of CA 125 are a well documented marker of
epithelial ovarian tumours (Bast et al., 1981; Brioschi et al.,
1987; Jacobs and Bast, 1989). Elevated serum CA 125 levels
have, however, also been observed in women with no ovarian
cancers but with advanced endometriosis (Patton et al., 1986),
pelvic inflammatory disease (Takahashi et al., 1990),
adenomyosis (Kijima et al., 1987), during menses (Takahashi
© Oxford University Press
et al., 1986) and during early pregnancy (Kobayashi et al., 1989;
Bischof etal., 1989).
By immunohistochemistry, CA 125 has been localized in the
epithelium of Fallopian tubes, endometrium and cervix but also
in mesothelial cells of pleura, pericardium and peritoneum,
whereas the ovary and its surface epithelium were negative for
CA 125 (Kabawat etal., 1983; de Bruijin etal., 1986;
Weintraub etal., 1990). The tissues) responsible for the
production of CA 125 in normal women has not been identified
with certainty. The endometrium is believed to be a potential
source of CA 125 since endometrial cells (Bischof et al., 1986;
Weintraub etal., 1990) or explants (Brumstead etal., 1990)
release CA 125 in vitro and since CA 125 concentrations are
particularly high in endometrial extracts (Jacobs et al., 1988).
Despite the fact that CA 125 cannot be localized immuno-
chemically in the ovary, this organ cannot be eliminated as a
potential source of the antigen. Indeed, CA 125 levels were high
in the luteal phase of women stimulated for in-vitro fertilization
(IVF) or intra-uterine insemination but not in unstimulated cycles
(Zweers et al., 1990). As suggested previously (Bischof et al.,
1989), the peritoneum is probably a major source of circulating
CA 125 at times other than pregnancy and menstruation, since
CA 125 is immunolocalized in the mesothelial cells of the
peritoneum and since pelvic inflammatory disease (Halila et al.,
1987) or ruptured ectopic pregnancy (Bischof et al., 1989) greatly
increase the serum levels of this antigen.
The purpose of the present study was to investigate the possible
use of serum CA 125 to monitor the regression of uterine fibroids
under gonadotrophin releasing hormone (GnRH) therapy. This
was based on the assumption that the presence of fibroids would
distend the peritoneum covering the uterus and thereby increase
CA 125 levels.
Materials and methods
The control group consisted of eight normal women (aged 28
to 35 years) with proven fertility in whom peripheral blood was
obtained on ethylenediaminotetraacetate (EDTA, 2 mg/ml) every
2 days starting immediately after the end of menstruation. Plasma
was stored at —20°C until assayed. Women with clinically
diagnosed uterine fibroids (n = 26, aged 22-55 years) were
divided into two groups: in group A (n = 16) the patients under-
went a hysterectomy by the vaginal or the abdominal route.
EDTA plasma was obtained prior to surgery and at 8 and 12
weeks thereafter and stored at -20°C. Uterine weight and
dimensions were recorded on the surgical specimen and the
uterine volume was approximated by multiplying the three dimen-
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sions. In group B (n = 10) the patients were treated by three
to four injections of a GnRH-agonist (GnRHa; Decapeptyl Retard,
3.7 mg/injection, Ferring, Switzerland) at 4-week intervals
starting between days 20 and 25 of the cycle. The size of myomata
was expressed as the product of three perpendicular diameters
measured at ultrasound; this was assessed before and every 4
weeks during GnRHa treatment. EDTA plasma was obtained
prior to and at 8 and 12 weeks during GnRHa treatment and
stored at -20°C until assayed. Cases with adenomyosis were
excluded from group A based on analysis of the surgical specimen
by the pathologist.
CA 125 was measured in all women using an immuno-
radiometric assay (Centocor, Medipro AG, Teufen, Switzerland).
Luteinizing hormone (LH) was measured in the control group
by a commercially available radioimmunoassay (Biom6rieux,
Geneva, Switzerland).
Statistical evaluation was performed on a Macintosh computer
by the Fastat program using Chi square, paired or unpaired f-test
whenever appropriate.
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Fig. 1. Concentration of CA 125 throughout the cycle in eight
normal women. Blood was not sampled during menses.
LH = luteinizing hormone.
Results
CA 125 levels during the cycle, control group
As shown in Figure 1, the levels of CA 125 plotted according
to the LH peak, did not change between the follicle and the luteal
phase of the cycle. For each patient, the mean CA 125 level
during each phase was calculated by averaging the individual
values. A paired f-test was used to evaluate the difference between
phases. No difference was observed between phases
(mean ± SEM, 15.0 ± 0.8 versus 16.8 ± 1.1 for prolifera-
tive versus secretory; P = 0.08; Table I), so that the normal
value of CA 125 was calculated by averaging all values from
all women.
The normal value of CA 125 during the cycle was
15.9 ± 0.7 IU/ml (mean ± SEM) with 90th centile at
26.2 IU/ml.
CA 125 levels in women with uterine fibroids
Before surgery or treatment, 10 out of 26 women with uterine
fibroids has increased CA 125 levels (higher than the 90th centile
of the normal population). This proportion was significantly
higher than in normal women (x2 = 13.101, P < 0.001). The
mean concentration of CA 125 was also significantly higher in
women with uterine fibroids as compared with normal women
(P < 0.0001, Table I). There was, however, no difference
in these parameters between those women who underwent
hysterectomy and those who received GnRHa (Table I). After
hysterectomy or during GnRHa therapy, the levels of CA 125
progressively and significantly decreased (paired r-test,
P = 0.004 and 0.009 for hysterectomy and GnRHa treatment
respectively) to levels observed during the cycle (Figure 2,
Table I) with no difference between patients subjected to
hysterectomy or GnRHa therapy. By 12 weeks of GnRHa treat-
ment or 12 weeks after hysterectomy, the levels of CA 125 were
significantly (P < 0.05) lower than those in the control group
(Table I). In terms of lowering the peripheral CA 125 concentra-
tions, both treatments were equally efficient.
Table I. Peripheral concentrations of CA 125
Type
Cycle control: Luteal*
Follicular*
Both*
n CA 125 IU/ml
52 16.8*
52 \5.&
103 15.^
Uterine fibroids before treatment:
for Hysterectomy
for GnRHa+
Both
16 45.2d
10 26.5=
26 38.0/
Uterine fibroids during or after treatment:
8 weeks post-hysterectomy
8 weeks of GnRHa
12 weeks post-hysterectomy
12 weeks of GnRHa
16 19.0"
10 12.5h
16 11.81
10 11.7J
SEM
1.1
0.8
0.7
13.1
6.3
8.5
3.5
2.2
1.8
2.8
Median
13.5
14.2
14.0
18.0
21.5
21.5
11.0
10.5
10.0
8.0
n above**
7/52
3/52
10/103 *
7/16
3/10
10/26'
4/16
1/10
1/16
1/10
Paired /-test: d versus g, P < 0.02; d versus i, P < 0.004; e versus h,
P < 0.02; e versus j , P < 0.001.
Unpaired /-test: c versus f, < 0.0001; c versus i, P < 0.05; c versus j ,
P < 0.05.
Chi square: k versus 1, P < 0.0001.
*Mean from the 8 normal women (see Figure 1).
•*n above: numbers of values above the 90th centile of the control group
(cycle control).
+GnRHa = gonadotrophin releasing hormone agonist.
CA 125 levels and uterine size
Among the patients who underwent a hysterectomy, there was
no correlation between the preoperative levels of CA 125 and
either the weight or the volume of the uterus as measured on
the surgical specimen. In contrast, in women who were treated
with GnRHa and on whom monthly ultrasound scans allowed
determination of the size of the myomata, the volume of these
was significantly correlated with the levels of CA 125 before and
during treatment (r = 0.442, P < 0.001). As shown in
Figure 3, in women myomata of < 100 ml the levels of CA 125
(mean ± SEM, 14.3 ± 1.9 IU/ml) were significantly lower
(P < 0.01) than in those with myomata volumes of >500 ml
(mean ± SEM, 33.0 ± 15.9 IU/ml).
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Fig. 2. Concentration of CA 125 in women with uterine fibroids, before and after hysterectomy (left panel) and before and during
gonadotrophin releasing hormone agonist (GnRHa) therapy.
Discussion
The CA 125 levels in normal women observed here correspond
to those described by others (Jacobs et al., 1988; Lanzone et al.,
1990), with no difference between the follicular and the luteal
phases of the cycle. The levels are, however, in contrast to those
observed by Jager et al. (1988) who reported an increase of
CA 125 which paralleled the growth of the dominant follicle.
Their observation is difficult to reconcile with the unchanging
levels of CA 125 during the first half of the cycle in women
stimulated for in-vitro fertilization (Lanzone et al., 1990; Zweers
et al., 1990) or with the absence of a difference between
ovulatory and anovulatory cycles (Lehtovirta et al., 1990).
In this study, more than one-third of the women with uterine
fibroids had increased CA 125 levels before surgery or treatment.
This observation is at variance with a study by Halila et al. (1987)
in which only two out of 11 women with uterine fibroids had
increased ( > 3 5 IU/ml) CA 125 levels before treatment. In the
present study, 10 out of 26 such women had levels of CA 125
above the 90th centile of the control group (26.2 IU/ml) and
among those, seven had values > 3 5 IU/ml, reaching as high
as 191 IU/ml. The discrepancy between these studies remains
unexplained. Since peripheral levels of CA 125 are correlated
with the volume of the myomata, and since increased
(>26 .2 IU/ml) CA 125 levels are mostly seen in women with
large ( > 300 ml) myomata, it is possible that in the study of Halila
et al. (1987), the majority of women had smaller uterine fibroids.
Here we observed that in women with fibroids, hysterectomy
or GnRHa therapy decreased the CA 125 concentrations to values
significantly below those of the control group. Thus in cases
where CA 125 is increased before treatment, this parameter could
serve to monitor GnRHa-induced myomata regression.
The origin of this increased CA 125 in women with uterine
fibroids is a matter of speculation. The uterus probably
only partially contributes to circulating CA 125, since after
hysterectomy or GnRHa therapy the peripheral levels of CA 125
are only slightly lower than during the normal cycle. However,
since the levels are still measurable after hysterectomy, a
contribution from another source has to be considered. The ovary
could potentially be a source of CA 125 but since in normal
women levels of CA 125 are identical in the ovarian vein and
>500
Volume of the Lelomyoma ml
Fig. 3. Relationship between peripheral CA 125 concentration and
the volume of leiomyomas as measured by ultrasound (n = 56
pairs of observations including values before and during therapy).
peripherally, (Bischof et al., unpublished), we considered it
unlikely that the ovary contributes significantly to the circulating
CA 125 in non-stimulated women. It is tempting to speculate that
the source of CA 125 is the peritoneum, since CA 125 was
localized immunohistochemically in this tissue (Kabawat et al.,
1983) and since serum CA 125 is increased in pelvic inflam-
matory disease (Takahashi etal., 1990), in ruptured ectopic
pregnancies (Bischof et al., 1989) or after laparoscopy for oocyte
retrieval (Zweers et al., 1990). If the peritoneum is a source of
CA 125 in vivo, then the increased levels of CA 125 in women
with uterine fibroids could be explained by peritoneal distension
due to the myomata. It must be added that the stratification of
the CA 125 values according to the location of the fibroids did
not show any significant difference between intramural, sub-
mucosal or subserosal fibroids.
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